Arch Therapeutics (Arch Therapeutics) Equity-to-Asset : -7.06 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Arch Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-10.88 Mil. Arch Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $1.54 Mil. Therefore, Arch Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was -7.06.

The historical rank and industry rank for Arch Therapeutics's Equity-to-Asset or its related term are showing as below:

ARTH' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.78 Med: -0.18 Max: 0.67
Current: -7.06

During the past 13 years, the highest Equity to Asset Ratio of Arch Therapeutics was 0.67. The lowest was -9.78. And the median was -0.18.

ARTH's Equity-to-Asset is ranked worse than
97.18% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ARTH: -7.06

Arch Therapeutics Equity-to-Asset Historical Data

The historical data trend for Arch Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Equity-to-Asset Chart

Arch Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Equity-to-Asset

Get a 7-Day Free Trial

-0.28

-0.70

-0.28

-1.61

-3.84

Arch Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial															-4.01	-5.13	-3.84	-5.26	-7.06

Competitive Comparison of Arch Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Arch Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Equity-to-Asset falls into.

Arch Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Arch Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Equity to Asset (A: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-7.508	/	1.958
	=	-3.83

Arch Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	-10.877	/	1.54
	=	-7.06

Arch Therapeutics (OTCPK:ARTH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Arch Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Therapeutics (Arch Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

235 Walnut Street, Suite 6, Framingham, MA, USA, 01702

Website

https://www.archtherapeutics.com

Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.

Executives

Terrence W Norchi	director, officer: President & CEO	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams	officer: CFO and Treasurer	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen	officer: Vice President, Sales	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat	director
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis	officer: CFO & Treasurer
Avtar S Dhillon	director	C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal	director	100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber	officer: Chief Financial Officer	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter	officer: Chief Operating Officer	C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616